Conclusion The findings of both scientific and clinical studies clearly indicate that clinical, patient-related and economic benefits are associated with the use of Mepilex Ag, Mepilex Border Ag and Mepilex Transfer Ag with Safetac in the treatment of wounds where antimicrobial activity is needed to help manage bioburden. As well as being clinically effective, they are reported to be cost-effective when used on wounds that require topical antimicrobial therapy. Studies reported that silver-containing foam dressings with Safetac are easy to use, provide an optimal environment for wound healing, and are associated with atraumatic and virtually painfree removal. In numerous clinical studies, silvercontaining foam dressings with Safetac were used to manage wound bioburden effectively and resolve signs of localised infection in both acute wounds (such as surgical, traumatic and burn injuries) and chronic wounds (such as leg ulcers, pressure ulcers (PUs), diabetic foot ulcers (DFUs), and cancerous wounds). Results In vitro test results showed that the silver-containing foam dressings with Safetac have both rapid and sustained activity against a range of wound pathogens, reducing planktonic and established biofilm cultures, and preventing biofilm formation. In addition, abstract books and proceedings documents relating to national and international conferences were scanned in order to identify presentations (oral, e-poster and poster) of relevance to the review. Method The MEDLINE (National Library of Medicine, Bethesda, US) and EMBASE (Elsevier BV, Amsterdam, Netherlands) bibliographic databases were searched. Aims A literature review was undertaken to identify and summarise clinical data from the entire evidence hierarchy, as well as data from in vitro tests, which support the use of silver-containing foam dressings with Safetac. The range comprises Mepilex Ag, Mepilex Border Ag and Mepilex Transfer Ag. To help improve wound management, dressings that use Safetac soft silicone technology in combination with a silver-impregnated foam dressing material were developed by Mölnlycke Health Care (Gothenburg, Sweden). Kristina was awarded her MSc in food science in 1997 from the University of Kalmar, Sweden, and in 2002 she was awarded a PhD for microbiological evaluation of novel technologies for food preservation by Chalmers Technical University, Gothenburg, Sweden.īackground Topical antimicrobials, such as silver dressings, are progressively being used alongside systemic antibiotics to provide adjunctive, antimicrobial therapy to wounds that are clinically infected or at risk of infection. During that time, she has become an expert within the areas of microbiology and test method development, as well as infection prevention. 3 Kristina Hamberg has over 10 years of experience of working with the design and development of wound care products, particularly those with antimicrobial properties.In 2014, she was awarded a PhD in the role and control of matrix metalloproteases in cutaneous wound healing. As a medical writer, she has also authored and contributed to a number of peer-reviewed journal articles and conference presentations. Since then, Sara has gained research experience in the field of wound healing. 2 Sara McCarty was awarded her BSc (Hons) in biomedical sciences in 2008 by the University of Chester, UK. Phil was awarded a BSc (Hons) Medical Cell Biology and Biochemistry by the University of Liverpool (United Kingdom) in 1989. During that time, he has authored and contributed to numerous peer-reviewed journal articles and conference presentations (oral and poster) relating to wound care and other areas of healthcare.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |